PMID- 29394600
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20180507
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 44
IP  - 12
DP  - 2017 Nov
TI  - [Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal 
      Endocrine-Responsive Metastatic Breast Cancer Patients].
PG  - 1260-1262
AB  - Everolimus and exemestane combination therapy represents a treatment option for 
      estrogen receptor(ER)-positive metastatic breast cancer. We evaluated the 
      efficacy and safety of everolimus and exemestane therapy, retrospectively. After 
      a median follow-up of 10.5 months, the median progression-free survivalin 
      patients was 4.7 months. The clinicalbenefit rate was 27%and the disease 
      controlrate was 64%. The most common all-grade adverse events(AEs)were 
      stomatitis(82%) and non-infectious lung disease(27%). The most commonB3 grade AEs 
      were cellulitis(18%)and hyperglycemia(18%). The AEs reported were mostly grade 1 
      and 2, and manageable with appropriate intervention. Combination therapy with 
      everolimus and exemestane appears to be a useful addition for ER-positive 
      metastatic breast cancer, with carefulmanage- ment of specific AEs.
FAU - Maeda, Noriko
AU  - Maeda N
AD  - Dept. of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University 
      Graduate School of Medicine.
FAU - Yamamoto, Shigeru
AU  - Yamamoto S
FAU - Sato, Yoko
AU  - Sato Y
FAU - Sakamoto, Kazuhiko
AU  - Sakamoto K
FAU - Suzuki, Nobuaki
AU  - Suzuki N
FAU - Takeda, Shigeru
AU  - Takeda S
FAU - Nagashima, Yukiko
AU  - Nagashima Y
FAU - Kubo, Hidefumi
AU  - Kubo H
FAU - Nagano, Hiroaki
AU  - Nagano H
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Androstadienes)
RN  - 9HW64Q8G6G (Everolimus)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Androstadienes/administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Endocrine System
MH  - Everolimus/administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Postmenopause
EDAT- 2018/02/06 06:00
MHDA- 2018/05/08 06:00
CRDT- 2018/02/04 06:00
PHST- 2018/02/04 06:00 [entrez]
PHST- 2018/02/06 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2017 Nov;44(12):1260-1262.